MétaCan
Menu
Back to cohort
Record W2905948744 · doi:10.1158/1078-0432.ccr-18-1726

SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance

2018· article· en· W2905948744 on OpenAlexaff
Isaac Wasserman, Lik Hang Lee, Shuji Ogino, Michael R. Marco, Chao Wu, Xi Chen, Jashodeep Datta, Eran Sadot, Bryan Szeglin, José G. Guillem, Philip B. Paty, Martin R. Weiser, Garrett M. Nash, Leonard B. Saltz, Afşar Barlas, Katia Manova‐Todorova, Srijaya Prakash Babu Uppada, Arthur E. Elghouayel, Peter Ntiamoah, Jonathan N. Glickman, Tsuyoshi Hamada, Keisuke Kosumi, Kentaro Inamura, Andrew T. Chan, Reiko Nishihara, Andrea Cercek, Karuna Ganesh, Nancy E. Kemeny, Punita Dhawan, Rona Yaeger, Charles L. Sawyers, Julio García‐Aguilar, Marios Giannakis, Jinru Shia, J. Joshua Smith

Bibliographic record

VenueClinical Cancer Research · 2018
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsUniversity of British Columbia
FundersOffice of Extramural Research, National Institutes of HealthNational Cancer InstituteSociety of Memorial Sloan KetteringNational Institute of Diabetes and Digestive and Kidney DiseasesStand Up To CancerAssociation for Academic SurgeryMemorial Sloan-Kettering Cancer CenterAmerican Society of Colon and Rectal SurgeonsAmerican College of SurgeonsU.S. Department of Veterans AffairsDana-Farber/Harvard Cancer CenterHoward Hughes Medical Institute
KeywordsCohortMedicineInterquartile rangeColorectal cancerInternal medicineOncologyCancerImmune systemChemotherapyGastroenterologyAdjuvant therapyImmunology

Abstract

fetched live from OpenAlex

Abstract Purpose: SMAD4 has shown promise in identifying patients with colorectal cancer at high risk of recurrence or death. Experimental Design: A discovery cohort and independent validation cohort were classified by SMAD4 status. SMAD4 status and immune infiltrate measurements were tested for association with recurrence-free survival (RFS). Patient-derived xenografts from SMAD4-deficient and SMAD4-retained tumors were used to examine chemoresistance. Results: The discovery cohort consisted of 364 patients with stage I–IV colorectal cancer. Median age at diagnosis was 53 years. The cohort consisted of 61% left-sided tumors and 62% stage II/III patients. Median follow-up was 5.4 years (interquartile range, 2.3–8.2). SMAD4 loss, noted in 13% of tumors, was associated with higher tumor and nodal stage, adjuvant therapy use, fewer tumor-infiltrating lymphocytes (TIL), and lower peritumoral lymphocyte aggregate (PLA) scores (all P < 0.04). SMAD4 loss was associated with worse RFS (P = 0.02). When stratified by SMAD4 and immune infiltrate status, patients with SMAD4 loss and low TIL or PLA had worse RFS (P = 0.002 and P = 0.006, respectively). Among patients receiving 5-fluorouracil (5-FU)-based systemic chemotherapy, those with SMAD4 loss had a median RFS of 3.8 years compared with 13 years for patients with SMAD4 retained. In xenografted mice, the SMAD4-lost tumors displayed resistance to 5-FU. An independent cohort replicated our findings, in particular, the association of SMAD4 loss with decreased immune infiltrate, as well as worse disease-specific survival. Conclusions: Our data show SMAD4 loss correlates with worse clinical outcome, resistance to chemotherapy, and decreased immune infiltrate, supporting its use as a prognostic marker in patients with colorectal cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesScience and technology studies
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.023
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.003
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.072
GPT teacher head0.444
Teacher spread0.372 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations100
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicCancer Immunotherapy and BiomarkersFrench-language works237,207